Edward Carr is CAO at Dianthus Therapeutics, Inc. /DE/ (DNTH). They have made 3 open-market trades across 2 companies since 2020, most recently 2026-09-17.
CIK 0001273351
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABEO | 400,169 | $1.8M |
| DNTH | 700 | $51K |
| Total | $1.8M |
Shares reported on the most recent Form 4, priced at the 2026-09-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DNTH | SELL · 10b5-1 | 2026-09-17 | 2026-09-18 | $101.38 | $2.0M | -8.1% | — | — |
| DNTH | SELL | 2026-03-12 | 2026-03-13 | $81.49 | $3.6M | +2.3% | +15.7% | -1.7% |
| ABEO | SELL · 10b5-1 | 2021-10-08 | 2021-10-08 | $1.05 | $31K | -6.5% | +0.7% | -67.3% |
| ABEO | SELL | 2021-04-01 | 2021-04-05 | $1.82 | $101K | -17.6% | -9.3% | -17.6% |
| ABEO | SELL | 2020-03-19 | 2020-03-20 | $1.81 | $12K | -6.6% | +17.8% | +46.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.